MARYLAND MEDICAID PHARMACY PROGRAM HEP C PROTEASE INHIBITOR RESPONSE-GUIDED THERAPY (RGT) GUIDELINES Boceprevir Response-Guided Therapy based on HCV RNA Treatment Response and Patient Characteristics HCV RNA Assessment at Treatment Weeka Total Population Regimen treatment Week 8 Week 12 Week 24 duration Treatment Naïve Undetectable Undetectable Undetectable PEG/riba for 4 weeks, 28 weeks (without cirrhosis) then boceprevir and PEG/riba for 24 weeks Detectable Undetectable Undetectable PEG/riba for 4 weeks, 48 weeks OR Detectable then boceprevir and PEG/riba for <100 IU/mL 32 weeks, then PEG/riba for 12 weeksb Treatment Naïve Undetectable Undetectable Undetectable PEG/riba for 4 weeks, 48 weeks OR Detectable Poorly Interferon OR Detectable then boceprevir and PEG/riba for Responsive <100 IU/mL 44 weeks (defined as HCV RNA decline <1.0 log10 at week 4) Prior Relapserc/Partial Undetectable Undetectable Undetectable PEG/riba for 4weeks, 36 weeks Responderd then boceprevir and PEG/riba for 32 weeks Detectable Undetectable Undetectable PEG/riba for 4weeks, 48 weeks OR Detectable then boceprevir and PEG/riba for <100 IU/mL 32 weeks, then PEG/riba for 12weeks Prior Null Respondere Undetectable Undetectable Undetectable PEG/riba for 4 weeks, 48 weeks OR Detectable OR Detectable then boceprevir and PEG/riba for <100 IU/mL 44 weeks Compensated Cirrhosis Undetectable Undetectable Undetectable PEG/riba for 4 weeks, 48 weeks OR Detectable (Treatment-naïve or OR Detectable then boceprevir and PEG/riba for <100 IU/mL 44 weeks
MARYLAND MEDICAID PHARMACY PROGRAM HEP C PROTEASE INHIBITOR RESPONSE-GUIDED THERAPY (RGT) GUIDELINES Boceprevir Response-Guided Therapy based on HCV RNA Treatment Response and Patient Characteristics Population HCV RNA Assessment at Treatment Weeka Regimen Total treatment duration Week 8 Week 12 Week 24 Treatment Naïve (without cirrhosis) Undetectable Undetectable Undetectable PEG/riba for 4 weeks, then boceprevir and PEG/riba for 24 weeks 28 weeks Detectable Undetectable OR Detectable <100 IU/mL Undetectable PEG/riba for 4 weeks, then boceprevir and PEG/riba for 32 weeks, then PEG/riba for 12 weeksb 48 weeks Treatment Naïve Poorly Interferon Responsive (defined as HCV RNA decline <1.0 log10 at week 4) Undetectable OR Detectable Undetectable OR Detectable <100 IU/mL Undetectable PEG/riba for 4 weeks, then boceprevir and PEG/riba for 44 weeks 48 weeks Prior Relapserc/Partial Responderd Undetectable Undetectable Undetectable PEG/riba for 4weeks, then boceprevir and PEG/riba for 32 weeks 36 weeks Detectable Undetectable OR Detectable <100 IU/mL Undetectable PEG/riba for 4weeks, then boceprevir and PEG/riba for 32 weeks, then PEG/riba for 12weeks 48 weeks Prior Null Respondere Undetectable OR Detectable Undetectable OR Detectable <100 IU/mL Undetectable PEG/riba for 4 weeks, then boceprevir and PEG/riba for 44 weeks 48 weeks Compensated Cirrhosis (Treatment-naïve or Undetectable OR Detectable Undetectable OR Detectable <100 IU/mL Undetectable PEG/riba for 4 weeks, then boceprevir and PEG/riba for 44 weeks 48 weeks
Hep%20C%20PI%20Response-Guided%20Therapy%20Guide%20Jun%201%202012.docx